Isavuconazole is a new antifungal prodrug to treat invasive aspergillosis and mucormycosis, theoretically not 22 requiring drug monitoring. However, we reported 4 clinical cases with toxic concentrations. Based on Desai's 23 population pharmacokinetic model, we estimated patients' kinetic profile. Clearance was abnormally low, 24 likely related to CYP3A4/5 polymorphisms. Thus, we recommend to collect blood sample just before the first 25 maintenance dose to estimate pharmacokinetic profile and individualized dose. For patients presenting high 26 concentrations, pharmacogenetics can be done. 27 2 Recently, Stott et al. [1] mentioned that "the novel broad-spectrum azole drug isavuconazole does not 28 currently appear to require TDM but 'real-world' data are awaited and TDM could be considered in selected 29 clinical cases". It did not take very long to confirm these proposals and even go further in the 30

